Get the Stockscreener App
2.84
13.15%
0.33
After Hours:
2.71
-0.13
-4.58%
Purple Biotech Ltd Adr stock is traded at $2.84, with a volume of 14,380.
It is up +13.15% in the last 24 hours and up +1.43% over the past month.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
See More
Previous Close:
$2.51
Open:
$2.54
24h Volume:
14,380
Relative Volume:
0.66
Market Cap:
$6.62M
Revenue:
-
Net Income/Loss:
$-19.88M
P/E Ratio:
-3.1209
EPS:
-0.91
Net Cash Flow:
$-19.93M
1W Performance:
+17.36%
1M Performance:
+1.43%
6M Performance:
-32.06%
1Y Performance:
-67.30%
1-Day Range:
$2.54
$2.84
1-Week Range:
$2.43
$2.84
52-Week Range:
$2.00
$20.60
Purple Biotech Ltd Adr Stock (PPBT) Company Profile
Compare PPBT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PPBT
Purple Biotech Ltd Adr
|
2.84 | 6.62M | 0 | -19.88M | -19.93M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Purple Biotech Ltd Adr Stock (PPBT) Latest News
Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial - GlobeNewswire Inc.
PPBT Stock Surges 150% on Superior Efficacy of PDAC Combo Therapy - Yahoo Finance
Why Purple Biotech (PPBT) Stock Is Getting Hammered - Benzinga
Purple Biotech Reports Third Quarter 2024 Financial Results - Yahoo Finance
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.65% - MSN
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.65% - MSN
PPBT stock touches 52-week low at $3.52 amid market challenges - Investing.com India
PPBT stock touches 52-week low at $5.89 amid market challenges - Investing.com
Purple Biotech price target raised by H.C. Wainwright, maintains Buy rating - Investing.com
PPBT stock touches 52-week high at $8.02 amid market fluctuations - Investing.com
What Makes Purple Biotech (PPBT) a New Buy Stock - Yahoo Finance
Purple Biotech stock target cut on trial cohort issue - Investing.com
95 Promising Stocks You Can Currently Buy for Less Than $5 Per Share - GOBankingRates
Purple Biotech stock retains Buy rating from H.C. Wainwright - Investing.com
Why Purple Biotech (PPBT) Shares Are Trading Lower - Benzinga
Here's Why Purple Biotech Ltd. Sponsored ADR (PPBT) Could be Great Choice for a Bottom Fisher - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts - Benzinga
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study - Yahoo Finance
Purple Biotech (PPBT) Stock Price, News & Analysis - MarketBeat
Market Data Center - Barron's
The FDA Just Approved Kitov's ConsensiNow What? (NASDAQ:PPBT) - Seeking Alpha
ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN
Purple Biotech Ltd Adr Stock (PPBT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):